New York University

Carlos Fernandez-Hernando

Kathryn J Moore

Katey J Rayner

Yajaira Suarez

Leigh Goedeke

Frederick Sheedy

The present invention relates to anti-miR-27b and anti-miR-148a oligonucleotides that are capable of decreasing the level and/or activity of miR-27b and miR-148a, respectively. In conjunction with the oligonucleotide molecules of the present invention, the invention also provides a method for decreasing the level and/or activity of miR-27b and/or miR-148a in a cell. In a further embodiment, the invention provides a method for treating a disease, especially dyslipidemias and cardiovascular diseases.

Anti-miR-27b and anti-miR-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases

The inhibition of miRNA miR-33 is shown to promote the polarization of macrophages from an M1 to an M2 phenotype. MiR-33 inhibitors are therefore useful for treating inflammation in subjects. Endogenous microRNAs can be silenced using antagomirs. The miR-33 inhibitor is preferably an antagomir having a single-stranded nucleic acid sequence that is complementary to at least 12 contiguous nucleotides in miR-33 and therefore forms a duplex with miR-33 under physiological conditions.

Growing community of inventors

Madison, CT, United States of America

Carlos Fernandez-Hernando